MAGE-A4 iPSC T-cell

MAGE-A4 iPSC T-cell is an investigational **allogeneic induced pluripotent stem cell derived T-cell therapy** being developed by Adaptimmune for solid tumors expressing **melanoma-associated antigen A4**. The product concept uses human iPSC-derived T cells engineered with a **MAGE-A4-specific T-cell receptor** to recognize tumor cells presenting a MAGE-A4 peptide in the context of compatible HLA, thereby redirecting cytotoxic T-cell killing against MAGE-A4-positive cancers. Publicly available information indicates this program has been described by Adaptimmune as an in-house preclinical allogeneic MAGE-A4-targeted iPSC T-cell product rather than a marketed or clinically named asset, so available details on the final construct, manufacturing process, and exact clinical indication remain limited.

Other names

MAGE-A4 iPSC T-cellMAGE-A-4 iPSC T-cellMAGE-A 4 iPSC T-cellMAGE-A4 targeted iPSC T-cellMAGE-A-4 targeted iPSC T-cellMAGE-A 4 targeted iPSC T-cellMAGE-A4 targeted productMAGE-A-4 targeted productMAGE-A 4 targeted product